Influenza drug oseltamivir has made vast amounts of pounds for Roche, but why wonвЂ™t the organization give patients and physicians usage of the total data that are clinical? Included in the BMJвЂ™s open information campaign, we this week introduce a brand new website committed to your cause. David Payne reports
This week the BMJ, included in its ongoing data that are open, has launched a separate website aimed at persuading Roche to provide physicians and clients usage of the total information on oseltamivir (Tamiflu).
The brand new website, shows e-mails and letters dating returning to September 2009, when researcher Tom Jefferson first asked the organization for the unpublished dataset utilized in a Roche supported analysis, posted in 2003.1
Jefferson required the info by the month that is following upgrade the Cochrane CollaborationвЂ™s review on neuraminidase inhibitors in healthy grownups. To start with the ongoing business asked him to signal a privacy agreement guaranteeing he will never publish the information in complete.2
Then it declined to provide it regarding the grounds it was in fact approached by an separate expert influenza team undertaking the same meta-analysis and wished to avoid a conflict. [Read more…] about Tamiflu: the battle for key drug information. Influenza drug oseltamivir has made billions